What happened with NSPR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
InspireMD makes devices for treating carotid artery disease. Its CGuard EPS and CGuard Prime products combine a self-expanding metal stent with MicroNet, a fine polymer mesh designed to keep plaque and clot debris from passing through the stent. The products use the same stent and mesh but different deployment mechanisms.
Most revenue comes from CGuard EPS sales outside the United States. Medical-product distributors buy the stents from InspireMD at fixed prices and handle local sales, marketing and registration. In the United States, InspireMD sells CGuard Prime through its own sales team and provides clinical support.
Sales depend on physicians choosing these devices and on local approval and reimbursement requirements. CGuard Prime has FDA approval for procedures that enter through an artery in the groin; its use through direct access to the carotid artery in the neck remains investigational and needs further approval.
Production relies on several single-source component suppliers, including the source of fiber for MicroNet. InspireMD is validating an alternative resin for that fiber, and certain material or supplier changes require FDA approval. Product sales do not yet cover the resources needed to run the business, so the company also depends on raising additional capital.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond this list, InspireMD faces carotid-stent rivals Cordis and Terumo and depends on Aptyx to expand CGuard Prime manufacturing capacity.
Boston Scientific competes with InspireMD to supply doctors with carotid-stenting devices; its Silk Road Medical business also competes in the TCAR market InspireMD is pursuing. Watch Silk Road Medical’s product news as InspireMD seeks CGuard Prime market share and develops SwitchGuard NPS.
Abbott sells carotid-stenting products that compete with InspireMD’s CGuard systems for use in the same treatment procedures. Watch whether its competing devices become easier to use or less costly—both are threats InspireMD identifies to its product revenue.
Medtronic supplies carotid-stenting products that compete with InspireMD’s CGuard systems in procedures to restore blood flow through the carotid artery. Its new products and improvements are worth watching: InspireMD warns that more effective alternatives could reduce its stent revenue.
LeMaitre Vascular supplies surgeons with carotid shunts and vascular patches for open surgery to remove carotid plaque, offering an alternative to treatment with InspireMD’s carotid stents.
Abbott Laboratories earningsABT
Abbott’s report can show how its medical-device business is doing; carotid-stent-specific information would show whether it is gaining in the same procedures where it competes with InspireMD.
Look for Abbott’s comments on carotid-stent demand and use, or on whether its devices are easier to use or less costly. Evidence of stronger demand or a more compelling product would mean doctors have a stronger competing option, making it harder for InspireMD to win use of CGuard; weakness in that specific business would point to less pressure. Abbott’s overall medical-device results, without carotid-stent detail, cannot establish whether this competition is heating up or easing.
InspireMD, Inc. earningsThis company
InspireMD’s report will show whether direct U.S. sales of CGuard Prime are growing enough to shift its sales mix and lift gross margin.
Compare U.S. revenue with international revenue, then read gross margin—the share of revenue left after product costs—alongside operating expenses and net loss. Rising U.S. sales with a higher margin and a narrowing loss would show that higher-priced, higher-margin direct sales are expanding and beginning to absorb commercialization costs. If U.S. sales remain weak, margin does not improve and losses stay large, international distributor sales still carry the business and the U.S. launch has not yet eased its financial strain.
